Pharmacological smoking cessation of adults aged 30–50 years with COPD

Dea Kejlberg Andelius*, Ole Hilberg, Rikke Ibsen, Anders Løkke


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

15 Downloads (Pure)


The prevalence of active smokers has remained relatively stable around 20% for several years in Denmark despite knowledge of the harmful effects. Smoking cessation is the most effective way to limit progression and reduce mortality of chronic obstructive pulmonary disease (COPD). Therefore, smoking cessation is particularly important among adults with COPD. The aim of this study was to determine the extent to which adults 30–50 years of age with COPD redeem pharmacotherapy for smoking cessation, and to identify demographic factors that influence the use of smoking cessation medication. We conducted a national retrospective non-interventional registry study, including all Danish patients with COPD (ICD-10 code J.44: chronic obstructive pulmonary disease) aged 30–50 years in the period 2009–2015. We identified 7734 cases, who were matched with controls (15,307) 1:2 on age, sex, and geography. Smoking status was not registered. We found that 18% of cases (with an estimated smoking prevalence at 33–50%) redeemed pharmacological smoking cessation medication in the study period compared to 3% of the controls (with an estimated smoking prevalence at 23%). The OR for cases collecting pharmacological smoking cessation medication was 5.92 [95% CI 5.24–6.70]. Male sex, being unemployed, and receiving social benefits were factors associated with less probability of redeeming pharmacological smoking cessation medication. Our study indicates that attention is needed on smoking cessation in adults aged 30–50 years with COPD, especially if unemployed or receiving social benefits, as these individuals are less likely to redeem pharmacological smoking cessation medication.

Tidsskriftnpj Primary Care Respiratory Medicine
Antal sider7
StatusUdgivet - 8. okt. 2022

Bibliografisk note

Funding Information:
The study was sponsored by Pfizer Denmark Aps.

Publisher Copyright:
© 2022, The Author(s).


Dyk ned i forskningsemnerne om 'Pharmacological smoking cessation of adults aged 30–50 years with COPD'. Sammen danner de et unikt fingeraftryk.